RITONAVIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ritonavir, and when can generic versions of Ritonavir launch?
Ritonavir is a drug marketed by Hikma, Mylan, Amneal, Aurobindo Pharma Ltd, Cipla, and Hetero Labs Ltd Iii. and is included in seven NDAs.
The generic ingredient in RITONAVIR is ritonavir. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ritonavir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ritonavir
A generic version of RITONAVIR was approved as ritonavir by CIPLA on January 15th, 2015.
Summary for RITONAVIR
Recent Clinical Trials for RITONAVIR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Taiwan University Hospital | Phase 2/Phase 3 |
Karolinska Institutet | Phase 2 |
Haukeland University Hospital | Phase 3 |
Pharmacology for RITONAVIR
Medical Subject Heading (MeSH) Categories for RITONAVIR
Anatomical Therapeutic Chemical (ATC) Classes for RITONAVIR
US Patents and Regulatory Information for RITONAVIR
EU/EMA Drug Approvals for RITONAVIR
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Mylan S.A.S | Ritonavir Mylan | ritonavir | EMEA/H/C/004549 Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older). |
Authorised | yes | no | no | 2017-11-09 | |
AbbVie Deutschland GmbH Co. KG | Norvir | ritonavir | EMEA/H/C/000127 Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older). |
Authorised | no | no | no | 1996-08-25 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |